Analyst Price Targets — OCGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 23, 2022 4:46 am | Uy Ear | Mizuho Securities | $5.00 | $2.34 | TheFly | Ocugen initiated with a Buy at Mizuho |
| August 15, 2022 11:41 am | — | H.C. Wainwright | $6.00 | $2.88 | Benzinga | HC Wainwright & Co. Maintains Buy on Ocugen, Lowers Price Target to $6 |
| June 18, 2022 2:00 pm | Jennifer Kim | Cantor Fitzgerald | $4.50 | $2.16 | Pulse 2.0 | Ocugen (OCGN) Stock Price: $4.50 Target And Overweight Rating |
| May 8, 2022 9:16 am | Daniil Gataulin | Chardan Capital | $3.50 | $2.16 | TheFly | Chardan keeps Neutral on Ocugen, lowers price target to $3.50 |
| April 25, 2022 2:12 am | Zegbeh Jallah | Roth Capital | $6.00 | $2.40 | Pulse 2.0 | Ocugen (OCGN) Stock: $6 Price Target And Buy Rating |
Latest News for OCGN
MALVERN, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that enrollment is now complete for the OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP). As a one-year clinical trial, topline data will be available in the first quarter of 2027. These data are…
MALVERN, Pa. , Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.
MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO).
MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced underwritten registered direct offering of 15,000,000 shares of its common stock at an offering price of $1.50 per share of common stock for net proceeds of $20.85 million, after deducting commissions and other…
Ocugen Inc (NASDAQ: OCGN) shares sank sharply on Wednesday after the biotech company announced a $22.5 million underwritten offering of common stock.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OCGN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.